Login to Your Account



Street’s post-RCC Cerulean wallop soothed via $1B NDC pact

By Randy Osborne
Staff Writer

Wednesday, October 19, 2016

Cerulean Pharma Inc. CEO Christopher Guiffre said his firm’s potential $1.1 billion agreement with Novartis AG could be “the deal that put us back on the map after the setback that we had in August.”

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription